CAMBRIDGE, Mass. (AP) _ Seres Therapeutics Inc. (MCRB) on Thursday reported a loss of $27.8 million in its second quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 68 cents.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 69 cents per share.

The drug developer posted revenue of $4.6 million in the period.

Seres Therapeutics shares have declined 24 percent since the beginning of the year. The stock has declined 43 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MCRB at https://www.zacks.com/ap/MCRB